{'fraction_non_alphanumeric': 0.03454038997214485, 'fraction_numerical': 0.012256267409470752, 'mean_word_length': 4.966777408637873, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prostatic Urethral Lift for Obstructive Median Lobes: Consistent Results Across Controlled Trial and Real-world Settings.

INTRODUCTION
Evidence for PUL in treating LUTS/BPH in men with obstructive median lobes (OML) has grown. Here, we present the first detailed comparison of outcomes between OML patients treated with PUL in controlled and real-world settings to relevant comparators (subjects treated with TURP and sham in randomized clinical trials [RCTs]) in order to demonstrate similar symptom, safety and patient experience outcomes.


METHODS
Symptom and safety outcomes and patient satisfaction were compared through 12 months among controlled PUL studies: BPH6 RCT (36 men randomized to TURP); L.I.F.T. pivotal RCT in subjects with lateral lobe obstruction (66 subjects randomized to sham) and MedLift, an FDA-approved IDE extension of the L.I.F.T. trial (45 men with OML). Symptom improvement, catheterization and adverse event rates were compared between MedLift subjects and OML patients (n=187) from the large real-word retrospective (RWR) study of PUL filtered on baseline characteristics to approximate the MedLift population.


RESULTS
Post-treatment, IPSS improvement for MedLift subjects was 170% greater than that of sham at 3 months with significantly better QoL, Qmax, and BPHII. Compared to TURP, MedLift IPSS and QoL improved significantly better at 1- and 3 months and with superior ejaculatory function scores at all timepoints after PUL. IPSS, QoL, PVR, and Qmax outcomes were equivalent between MedLift and RWR OML groups at 3-, 6-, and 12 months. RWR OML patients did not experience higher rates of overall AEs compared to MedLift.


CONCLUSION
Controlled and real-world outcomes confirm PUL is a safe and effective treatment for BPH patients with and without OML.